Abstract
Platelet monoamine oxidase (MAO) activity has been studied extensively since Murphy and Wyatt (1972) reported low levels of this enzyme in the platelets of chronic schizophrenics. Some investigators, however, have been unable to demonstrate reduced MAO activity in schizophrenics (Wyatt et al. 1980). Consequently, recent work in this field has attempted to elucidate specific clinical criteria to distinguish schizophrenics with low MAO levels. To date, differences between paranoid and nonparanoid schizophrenics with regard to MAO activity have been most often noted. In contrast, relatively little is known about the possible relevance of negative versus positive symptoms to MAO activity. As far as the effect of medication is concerned, there is also disagreement over whether
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
